NeuroSense Therapeutics (NRSN) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company developing treatments for neurodegenerative diseases, focusing on ALS, Alzheimer's, and Parkinson's disease.

• Lead candidate PrimeC is a novel oral fixed-dose combination of ciprofloxacin and celecoxib, targeting multiple ALS disease pathways.

• PrimeC has orphan drug designation from both FDA and EMA and is advancing toward a pivotal Phase III trial in ALS.

• Additional pipeline candidates are in development for Alzheimer's and Parkinson's using a similar combined product strategy.

Financial performance and metrics

• April 2024 registered direct offering raised $4.47 million gross; August 2024 private placement raised $600,000 net; December 2024 private placement expected to raise $5.0 million gross.

• As of June 30, 2024, pro forma cash was $7.9 million, with shareholders' equity of $4.99 million after recent financings.

• Ongoing concern noted in audit report due to recurring losses and expectation of significant additional losses.

Use of proceeds and capital allocation

• No proceeds from resale by selling shareholder; company will receive proceeds only if warrants are exercised for cash.

• Any proceeds from warrant exercises will fund clinical development of PrimeC for ALS, R&D for Alzheimer's and Parkinson's, new product candidates, and general corporate purposes.